
Yevgeny Valenrod
Examiner (ID: 12175, Phone: (571)272-9049 , Office: P/1672 )
| Most Active Art Unit | 1628 |
| Art Unit(s) | 1628, 1621, 1672 |
| Total Applications | 1538 |
| Issued Applications | 1086 |
| Pending Applications | 107 |
| Abandoned Applications | 372 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19290369
[patent_doc_number] => 12029708
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-09
[patent_title] => Alkoxy compounds for disease treatment
[patent_app_type] => utility
[patent_app_number] => 17/817927
[patent_app_country] => US
[patent_app_date] => 2022-08-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 102149
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17817927
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/817927 | Alkoxy compounds for disease treatment | Aug 4, 2022 | Issued |
Array
(
[id] => 17944291
[patent_doc_number] => 20220331308
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-20
[patent_title] => OPHTHALMIC COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 17/858889
[patent_app_country] => US
[patent_app_date] => 2022-07-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4892
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17858889
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/858889 | Ophthalmic compositions | Jul 5, 2022 | Issued |
Array
(
[id] => 20171745
[patent_doc_number] => 12390465
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-19
[patent_title] => Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder
[patent_app_type] => utility
[patent_app_number] => 17/850463
[patent_app_country] => US
[patent_app_date] => 2022-06-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 2070
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 117
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17850463
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/850463 | Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder | Jun 26, 2022 | Issued |
Array
(
[id] => 18619130
[patent_doc_number] => 11752152
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2023-09-12
[patent_title] => Pharmaceutical formulations of imatinib and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/850322
[patent_app_country] => US
[patent_app_date] => 2022-06-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15716
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 85
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17850322
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/850322 | Pharmaceutical formulations of imatinib and uses thereof | Jun 26, 2022 | Issued |
Array
(
[id] => 19675848
[patent_doc_number] => 12187698
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-07
[patent_title] => Crystalline forms of C
[patent_app_type] => utility
[patent_app_number] => 17/842632
[patent_app_country] => US
[patent_app_date] => 2022-06-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 20328
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 290
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17842632
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/842632 | Crystalline forms of C | Jun 15, 2022 | Issued |
Array
(
[id] => 17895333
[patent_doc_number] => 20220304995
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-29
[patent_title] => OPHTHALMIC COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 17/841433
[patent_app_country] => US
[patent_app_date] => 2022-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4890
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 1
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17841433
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/841433 | OPHTHALMIC COMPOSITIONS | Jun 14, 2022 | Abandoned |
Array
(
[id] => 18267845
[patent_doc_number] => 20230089087
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-23
[patent_title] => COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY
[patent_app_type] => utility
[patent_app_number] => 17/839169
[patent_app_country] => US
[patent_app_date] => 2022-06-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5450
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17839169
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/839169 | Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency | Jun 12, 2022 | Issued |
Array
(
[id] => 19418400
[patent_doc_number] => 20240294523
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-05
[patent_title] => HETEROCYCLIC LACTAM COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/568791
[patent_app_country] => US
[patent_app_date] => 2022-06-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30233
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18568791
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/568791 | HETEROCYCLIC LACTAM COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Jun 9, 2022 | Pending |
Array
(
[id] => 18246000
[patent_doc_number] => 11602563
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-03-14
[patent_title] => Pharmaceutical compositions comprising meloxicam
[patent_app_type] => utility
[patent_app_number] => 17/837790
[patent_app_country] => US
[patent_app_date] => 2022-06-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 35
[patent_no_of_words] => 24941
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17837790
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/837790 | Pharmaceutical compositions comprising meloxicam | Jun 9, 2022 | Issued |
Array
(
[id] => 18064412
[patent_doc_number] => 20220395499
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-15
[patent_title] => CONTROLLING EFFECTS AFTER 5HT2A AGONISTS ADMINISTRATION
[patent_app_type] => utility
[patent_app_number] => 17/833829
[patent_app_country] => US
[patent_app_date] => 2022-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3413
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -45
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17833829
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/833829 | CONTROLLING EFFECTS AFTER 5HT2A AGONISTS ADMINISTRATION | Jun 5, 2022 | Abandoned |
Array
(
[id] => 19263586
[patent_doc_number] => 20240207283
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-27
[patent_title] => WATER SOLUBLE COMPLEX COMPOSITIONS AND METHODS THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/565487
[patent_app_country] => US
[patent_app_date] => 2022-05-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9488
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18565487
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/565487 | WATER SOLUBLE COMPLEX COMPOSITIONS AND METHODS THEREOF | May 26, 2022 | Pending |
Array
(
[id] => 19343540
[patent_doc_number] => 20240252503
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-01
[patent_title] => METHODS OF TREATMENT
[patent_app_type] => utility
[patent_app_number] => 18/565626
[patent_app_country] => US
[patent_app_date] => 2022-05-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9967
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18565626
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/565626 | METHODS OF TREATMENT | May 26, 2022 | Pending |
Array
(
[id] => 18449450
[patent_doc_number] => 20230190726
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING NEGATIVE SYMPTOMS IN NON-SCHIZOPHRENIC PATIENTS
[patent_app_type] => utility
[patent_app_number] => 17/825783
[patent_app_country] => US
[patent_app_date] => 2022-05-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8498
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17825783
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/825783 | COMPOSITIONS AND METHODS FOR TREATING NEGATIVE SYMPTOMS IN NON-SCHIZOPHRENIC PATIENTS | May 25, 2022 | Abandoned |
Array
(
[id] => 19331211
[patent_doc_number] => 20240245641
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-25
[patent_title] => PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES MELLITUS IN ANIMAL OF FAMILY CANIDAE, COMPRISING ENAVOGLIFLOZIN
[patent_app_type] => utility
[patent_app_number] => 18/562428
[patent_app_country] => US
[patent_app_date] => 2022-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4772
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18562428
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/562428 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES MELLITUS IN ANIMAL OF FAMILY CANIDAE, COMPRISING ENAVOGLIFLOZIN | May 19, 2022 | Pending |
Array
(
[id] => 19667426
[patent_doc_number] => 12180153
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-12-31
[patent_title] => Method of treating ocular disorders with compounds found in Harderian gland secretions
[patent_app_type] => utility
[patent_app_number] => 17/749583
[patent_app_country] => US
[patent_app_date] => 2022-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 9
[patent_no_of_words] => 8502
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17749583
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/749583 | Method of treating ocular disorders with compounds found in Harderian gland secretions | May 19, 2022 | Issued |
Array
(
[id] => 20039131
[patent_doc_number] => 20250177353
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-06-05
[patent_title] => METHODS OF TREATING MITOCHONDRIA-RELATED DISORDERS
[patent_app_type] => utility
[patent_app_number] => 18/562560
[patent_app_country] => US
[patent_app_date] => 2022-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20348
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18562560
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/562560 | METHODS OF TREATING MITOCHONDRIA-RELATED DISORDERS | May 18, 2022 | Pending |
Array
(
[id] => 19447279
[patent_doc_number] => 20240307409
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-19
[patent_title] => ARGININE METHYLTRANSFERASE INHIBITOR AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/562419
[patent_app_country] => US
[patent_app_date] => 2022-05-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24342
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 836
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18562419
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/562419 | ARGININE METHYLTRANSFERASE INHIBITOR AND USE THEREOF | May 17, 2022 | Pending |
Array
(
[id] => 18107888
[patent_doc_number] => 20230000768
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-05
[patent_title] => POLYMERIC EMULSION DELIVERY SYSTEMS
[patent_app_type] => utility
[patent_app_number] => 17/747938
[patent_app_country] => US
[patent_app_date] => 2022-05-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12522
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -38
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17747938
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/747938 | POLYMERIC EMULSION DELIVERY SYSTEMS | May 17, 2022 | Pending |
Array
(
[id] => 19380862
[patent_doc_number] => 20240270732
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-15
[patent_title] => RECEPTOR-INTERACTING PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/562555
[patent_app_country] => US
[patent_app_date] => 2022-05-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17253
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18562555
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/562555 | RECEPTOR-INTERACTING PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | May 16, 2022 | Pending |
Array
(
[id] => 17911273
[patent_doc_number] => 20220313668
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-06
[patent_title] => METHOD OF TREATING LIVER FIBROSIS
[patent_app_type] => utility
[patent_app_number] => 17/662979
[patent_app_country] => US
[patent_app_date] => 2022-05-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9226
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 107
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17662979
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/662979 | METHOD OF TREATING LIVER FIBROSIS | May 10, 2022 | Abandoned |